English

Better health and quality of life for patients with rare diseases in Norway

Koalisjonen is the pharmaceutical industry’s interest group for rare diseases in Norway. Ten pharmaceutical companies stand behind it.

Key figures

Copy a sentence with its source.

Who we are

An industry collaboration for the rare disease field

Koalisjonen is a collaboration between ten pharmaceutical companies: Sanofi, Takeda, Biogen, BioMarin, Chiesi, Italfarmaco, Merck, Alexion, Lundbeck and CSL.

Since 2015, Koalisjonen has worked for predictable framework conditions for the treatment of rare diseases, through policy input, events and public debate. Koalisjonen works at system level and does not engage in matters concerning individual products.

Rare diseases in Norway

Rare one by one, many together

320,000

people in Norway live with a rare diagnosis, by the upper estimate

6,000+

rare diagnoses have been described

72%

of the diagnoses are genetic

95%

of rare diseases have no approved treatment

Sources: Norwegian National Centre for Rare Diagnoses (2026) and EURORDIS (2026). A disease is rare when it affects fewer than 1 in 2,000 people.

Goals

What we work for

Rapid and equitable access

We work for frameworks and priorities that give patients with rare diseases rapid and equitable access to medicines.

Knowledge and the patient perspective

We strengthen the knowledge base on rare conditions and work to ensure that the experiences of patients and their families inform decisions.

A network across the rare disease field

We build meeting places for patients, clinicians, decision makers and others who work with rare diseases.

Members

Ten companies stand behind Koalisjonen

Alexion
Biogen
BioMarin
Chiesi
CSL
Italfarmaco
Lundbeck
Merck
Sanofi
Takeda
Contact

Get in touch

post@koalisjonenforsjeldnesykdommer.no
+47 976 35 417

Most of the content on this site is published in Norwegian.

Would you like to know more about our work?